EACS 2023 Symposium - The Devil Wears GP120
What's New
We are pleased to look back on the very successful symposium "The Devil Wears GP120".
The Program Chair and organizers would like to thank the chair, the speakers, and all participants for their contribution and attendance in this symposium!
About this Symposim
Insight into HIV pathogenesis have been key to developing antiretroviral drugs and improving management of people living with HIV. GP120 plays a major role in HIV binding to target cells, but recent studies suggest GP120 may play a much greater role in HIV interactions with the immune system and the appearance of comorbidities. An improved understanding of these interactions may help overcome some of the remaining unmet needs of people living with HIV.
A deeper understanding of GP120 and its relevance as a therapeutic target might be improving the immune reconstitution of patients with poor or partial CD4 responses to suppressive therapy. Although CD4 cells and CD4/CD8 ratios improve in most individuals living with HIV after HIV RNA suppression is maintained, these responses can be blunted in some people living with HIV, such as heavily treatment-experienced individuals and of those starting therapy with very low CD4 counts. Inhibition of GP120 might provide clinical benefit in this population. Additional negative GP120 effects on immune and inflammatory responses might be favourably manipulated with drugs targeting this molecule. This program aims to educate clinicians on recent advances in the study of GP120, and review both basic science as well as clinical data relevant to the topic.